According to Amaria, early data from the phase 1 study, including findings presented at the 2024 American Society of Clinical Oncology Annual Meeting were encouraging, as OBX-115 was shown to be well-tolerated and did not lead to any severe adverse events.
2025
Maximizing Impact and Utility of Prognostic Gene Testing in Melanoma and Squamous Cell Carcinoma
An expert explores how prognostic gene expression testing enhances risk stratification and guides personalized treatment in melanoma and squamous cell carcinoma, and also shares clinical insights and practice pearls from my experience using these tests.
A Novel Immunotherapy Strategy May Improve Melanoma Treatment
A study has uncovered a novel method to enhance immunotherapy for melanoma by targeting a protein known as macrophage receptor with collagenous structure, or MARCO. The findings showed that blocking MARCO in combination with anti-CTLA4 therapy appreciably slows tumor progression in melanoma. The findings were reported in Journal for ImmunoTherapy of Cancer.
Pembrolizumab Plus Bevacizumab Shows Promise for Melanoma Brain Metastases
The anti–PD-1/VEGF combination of pembrolizumab and bevacizumab elicited strong clinical activity in patients with melanoma brain metastases.